Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Adc Therapeutics SA’s stock clocked out at $4.11, down -10.85% from its previous closing price of $4.61. In other words, the price has decreased by -$10.85 from its previous closing price. On the day, 1.94 million shares were traded. ADCT stock price reached its highest trading level at $4.625 during the session, while it also had its lowest trading level at $4.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share. On Dec 04 ’24, another insider, Redmile Group, LLC, who serves as the 10% Owner of the company, sold 25,352 shares for $2.07 each. As a result, the insider received 52,479 and left with 15,566,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 518622240 and an Enterprise Value of 648579520. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.99. Its current Enterprise Value per Revenue stands at 8.396 whereas that against EBITDA is -5.142.
Stock Price History:
The Beta on a monthly basis for ADCT is 1.95, which has changed by 0.27639747 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $4.74, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 19.12%, while the 200-Day Moving Average is calculated to be 69.40%.
Shares Statistics:
It appears that ADCT traded 824.53K shares on average per day over the past three months and 1333350 shares per day over the past ten days. A total of 112.50M shares are outstanding, with a floating share count of 88.15M. Insiders hold about 21.64% of the company’s shares, while institutions hold 58.97% stake in the company. Shares short for ADCT as of 1759190400 were 5298345 with a Short Ratio of 6.43, compared to 1756425600 on 4143356. Therefore, it implies a Short% of Shares Outstanding of 5298345 and a Short% of Float of 5.81.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.23 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.38 and -$1.73 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is -$1.29, with 5.0 analysts recommending between -$0.8 and -$1.97.
Revenue Estimates
In . The current quarter, 6 analysts expect revenue to total $17.98M. It ranges from a high estimate of $19.3M to a low estimate of $16.37M. As of . The current estimate, Adc Therapeutics SA’s year-ago sales were $18.46MFor the next quarter, 6 analysts are estimating revenue of $18.69M. There is a high estimate of $19.55M for the next quarter, whereas the lowest estimate is $17.5M.
A total of 6 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $80.5M, while the lowest revenue estimate was $76.8M, resulting in an average revenue estimate of $78.54M. In the same quarter a year ago, actual revenue was $70.84MBased on 5 analysts’ estimates, the company’s revenue will be $81.24M in the next fiscal year. The high estimate is $98.2M and the low estimate is $72.6M.
